Asia Business News

Lee's Pharmaceutical Holdings Limited's (HKG:8221) Profit Surged 86% in 1Q2009 Achieved Nine Consecutive Quarters of Double Digit Growth

Friday May 15 3:02 PM

Hong Kong, China, May 15, 2009 - (ABN Newswire) - Lee's Pharmaceutical Holdings Limited's (HKG:8221) today announced its unaudited consolidated results for the three months ended 31 March 2009 (the "period under review").

As an integrated research-driven and market-oriented pharmaceutical group in China, Lee's Pharmaceutical continued to benefit from the increasing sales of all products especially Iron Proteinsuccinylate Oral Solution which achieved the highest increment of 288%. During the period, the Group achieved a revenue of approximately HK$33.0 million, representing a 46.7% growth compared with the same period of last year.

The Group recorded solid results during the period under review, keeping pace with the growth momentum of 2008. Gross profit increased to approximately HK$23.6 million and profit attributable to shareholders surged by 86.1% to approximately HK$ 7.8 million. During the period under review, the gross profit margin of the Group increased from 70.7 % in 2008 to 71.4% in 2009. This improvement was mainly due to the decrease in cost of Carnitene(R).

In March 2009, the Group successfully concluded a license agreement with a premium Japanese pharmaceutical company, Nippon Shinyaku Co. Ltd. (TYO:4516) for the pharmaceutical product containing antibacterial agent "Prulifloxacin" for the treatment of urinary tract infections and respiratory tract infections.

Commenting on the Group's outstanding performance, Dr. Benjamin Li, CEO of the Group said, "Riding on the growth momentum of 2008, the Group was able to achieve satisfactory results during the period under review. The Group entered into cooperation with Nippon Shinyaku Co., Ltd. which represents a significant breakthrough in the Group's corporate development. With our renowned brand and abundant experiences in China, Lee's Pharmaceutical becomes a preferred partner in China for the worldwide research-based pharmaceutical companies, making it possible for us to further strengthen our pipeline and maintain our rapid growth."

Dr Li continued, "Both Veloderm(R) and Challenger balloon, our license-in products, are entering the final stage of registration. Their import licenses are expected to be granted in the coming quarters. These products will offer new growth opportunities for us and enhance our sustainability. Looking ahead, we are confident that the sales of all existing products will sustain in current rapid growth trend, bringing desirable returns to our shareholders."
Financial Highlight (For the three months ended 31 March)
------------------------------------------------------
                           2009         2008    Change
                       (HK$'000)    (HK$'000)     (%)
------------------------------------------------------
Turnover                 33,035       22,513    +46.7%
Gross Profit             23,602       15,918    +48.3%
Gross Profit Margin       71.4%        70.7%   +0.7%pt
Profit Attributable 
to Shareholders           7,802        4,193    +86.1%
Earnings per Share
(Basic)             HK1.88cents  HK1.01cents    +86.1%
------------------------------------------------------


About Lee's Pharmaceutical Holdings Limited :

Lee's Pharmaceutical Holdings Limited (8221.HK) is a public biopharmaceutical company with over 14 years operation in China's pharmaceutical industry. It is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives and currently markets six products. Lee's Pharm focuses on several different areas such as cardiovascular and infectious diseases, dermatology, oncology, gynecology and others. It has more than 20 products under different development stages stemming from both internal R&D as well as from the recent acquisition of licensing and distribution rights from various US and European companies. The mission of Lee's Pharm is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life.

Contact:
Porda International (Finance) P.R. Company Limited

Keely Chan
Tel: +852-3150-6760/ +852-9770-2950
keely.chan@pordafinance.com.hk

Alman Loong
Tel: +852-3150-6731/ +852-9107-8225
alman.loong@pordafinance.com.hk

Liz Yip
Tel: +852-3150-6739/ +852-9497-1685
liz.yip@pordafinance.com.hk
Fax: +852-3150-6728
 


Source:

Lee's Pharmaceutical Holdings Limited

Copyright (C) 2009 ABN Newswire. All rights reserved.
ABN Newswire

All Stories


Related Quotes
chart All Detailed Quotes
Delayed 20 mins
Quote data provided by Reuters
Top Stories
· ECB hikes inflation forecasts for 2009, 2010 - AFP Business News, ( Thursday September 3, 2009, 11:16 pm)
· Shareholders could reject CEO payouts - AAP, ( Thursday September 3, 2009, 10:53 pm)
· CBA feels wrath over Storm collapse - ABC Business News, ( Thursday September 3, 2009, 9:55 pm)
· BankWest facing possible class action - AAP, ( Thursday September 3, 2009, 9:32 pm)
More...

Finance Message Boards
Most recent posts:
fast and eassy money4
Gold and Silver1781
Predict house prices to drop 40-50%2094
Padbury (PDY)3
ASIclub - An A1 network.12
More Finance Boards

Email this Article Email this story - Print this Article  Printer friendly version

Next article:Carbon Energy Limited (ASX:CNX) Clarifying Statement to the announcement made on 13 May 2009 (MD's Presentation at the Sydney Resources Round-up Confe
Previous article:Bandanna Energy Limited (ASX:BND) Announces Approval Of Application For New Coal Exploration Permit In Bowen Basin



Copyright © 2009 Yahoo!7 Pty Limited. All rights reserved.
Advertise with Us - Privacy Policy - Terms of Service.